ClinicalTrials.gg
RecruitingNCT07588932Updated Jul 14, 2026

Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors

An Early Phase 1 interventional study of Telmisartan, Metformin, Cilostazol in Stroke, sponsored by Spaulding Rehabilitation Hospital. Recruiting at 1 site in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Spaulding Rehabilitation Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies in Stroke by Spaulding Rehabilitation Hospital — 9 open to participants now, 10 under way, none of them phase 3. Stroke · Spaulding Rehabilitation Hospital.

Planned enrollment
4th of 20
50 · median 39
Started
2026
with 3 others
Phase 1
Only one
of the 20
Registered
19th of 20
by date

Among the 20 studies in Stroke by Spaulding Rehabilitation Hospital, this one is the 4th largest by planned enrollment, is one of 4 that started in 2026, is the only one in phase 1, and was the 19th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 20 studies in Stroke by Spaulding Rehabilitation Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Stroke by Spaulding Rehabilitation Hospital, or all of them as a file.
02

Study summary

The goal of this trial is to study if the concomitant administration of Telmisartan, Cilostazol IR (immediate release), and Metformin ER (extended release) can help stroke survivors make greater gains in movement and recovery during robot-assisted arm and hand rehabilitation.

Read the detailed description

The overall objective of the proposed study is to assess the viability of a pharmacotherapy combining Telmisartan, Cilostazol IR, and Metformin ER to affect the motor gains achieved via robot-assisted (RA) upper-extremity (UE) rehabilitation in stroke survivors. The hypothesis underlying the study design is that concomitant administration of Telmisartan, Cilostazol IR, and Metformin ER (herein referred to as "the proposed pharmacotherapy") leads to enhancing motor and non-motor gains observed in stroke survivors in response to RA UE rehabilitation. Participants will take these medications either once a day (QD) or twice a day (BID) as described in the protocol.

To test this hypothesis, we plan to accomplish the following primary and secondary aims.

Primary Aims:

  • 1 To determine if administration of the proposed pharmacotherapy in combination with RA UE rehabilitation leads to greater improvements in UE motor impairment than previously observed in clinical trials relying on RA UE rehabilitation alone.
  • 2 To evaluate potential adverse events when using the proposed pharmacotherapy in combination with RA UE rehabilitation.

Secondary Aim:

#1 To determine if the proposed pharmacotherapy in combination with RA UE rehabilitation improves UE functional ability, health related quality of life, and cognition.

Exploratory Aims:

  • 1 To determine the association between response to the proposed pharmacotherapy and serum-based biomarkers collected at baseline (i.e., evaluation session prior to training), during the first training session (beginning and end of the session), during the last training session (beginning and end of the session), and during the 3-month follow-up evaluation session.
  • 2 To evaluate the retention of motor and cognitive gains at 1-month post-intervention.
03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Stroke
  • Rehabilitation
  • Pharmacotherapy
  • Robotic therapy
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between 21 and 80 years of age.
  • History of ischemic stroke.
  • Stroke occurred at least six months prior to recruitment.
  • Moderate to severe UE impairment (FMA-UE score between 15 and 40)
  • score >=20 and being able to safely follow three-step commands.

Exclusion criteria

Exclusion Criteria:

  • to the pharmacotherapy (e.g., heart failure, known medication reaction or interactions with ongoing medication regimen).
  • Taking dual antiplatelet therapy (e.g., Aspirin+Plavix) and/or other anticoagulation medications (e.g., Eliquis, coumadin) that cannot safely be modified or discontinued (as determined by the participant's primary care physician or by the medical monitor).
  • somnolence and/or depression that would hinder active participation in motor training sessions.
  • Taking any medication that the study physician determines to have a significant drug-drug interaction with Telmisartan, Cilostazol, and/or Metformin.
  • Taking Telmisartan, Cilostazol, and/or Metformin in a dose that is different from the one used in the study and that cannot be adjusted to match the study dose (as determined by the participant's primary care physician or by the medical monitor).
  • Taking medications with equivalent clinical effect (e.g., BP control) to Telmisartan, Cilostazol, and/or Metformin and that cannot be replaced by Telmisartan, Cilostazol, and/or Metformin (as determined by the participant's primary care physician or by the medical monitor).
  • A (BMI) below 25 (as the proposed pharmacotherapy could cause hypoglycemia in participants with normal-low BMI).
  • Severe musculoskeletal pathology or recent fractures affecting the impaired UE that would prevent safe use of the rehabilitation robotic system.
  • Previous diagnosis of neurological diseases other than stroke that would have a negative impact on the response to the rehabilitation intervention (e.g., severe dystonia affecting the UE) or would prevent safe participation in RA UE training (e.g., uncontrolled seizures).
  • Moderate to severe disability due to migraines as determined using the Migraine Disability Assessment test (score > 10).
  • Severe spasticity (Modified Ashworth Scale for spasticity ≥ 3 for UE muscles) that would prevent safe use of the robotic system utilized during training.
  • Undergoing Botox treatment for pain/spasticity related to the affected upper extremity, in the 4 months prior to enrollment or during the study period.
  • Cerebellar and/or hemorrhagic stroke.
  • Severe aphasia limiting the ability to express needs or discomfort verbally or non-verbally.
  • Visual impairments that would prevent proper use of interactive on-screen games during RA UE training.
  • Severe hemispatial neglect as assessed using the Line Bisection Test (missed lines >2).
  • Severely impaired trunk control that would prevent sitting safely on a chair without arms.
  • Individuals who present with the following on the impaired UE: open wounds, fragile skin, and under contact precautions due to an active infection.
  • Participation in another therapy focused on the recovery of the impaired UE.
  • Subjects with cardiac pacemakers, electronic pumps, or any other implanted medical devices that are not US-certified (and hence might be affected by the electromagnetic interference generated by the robot).
  • Any condition that would prevent proper/safe use of the robotic system, such as proprioceptive deficits that impair the ability to process haptic or visual feedback, or unstable shoulder joint as assessed by physical examination.
  • Current pregnancy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants will be instructed to take Telmisartan, Cilostazol IR (immediate release), and Metformin ER (extended release) (herein referred to as "proposed pharmacotherapy") while undergoing robot-assisted upper-extremity training. Participants will take these medications either once a day (QD) or twice a day (BID) as described in the protocol.

    Drug: Telmisartan, Metformin, Cilostazol

Interventions

  • DrugTelmisartan, Metformin, Cilostazol

    Drug pages: TelmisartanStudies of TelmisartanTelmisartan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CilostazolStudies of CilostazolCilostazol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be instructed to take the low dose of the proposed pharmacotherapy (i.e., Telmisartan 20mg QD, Metformin ER 500mg QD, Cilostazol IR 50mg QD) during week 1 and the full dose (i.e., Telmisartan 40mg QD, Metformin ER 500mg BID, Cilostazol IR 50mg BID) starting on week 2. They will continue to take the full dose until completion of the six-week robot assessed upper extremity training period (week 3-8). At the end of this period, they will be instructed to take the low dose of the proposed pharmacotherapy for two more weeks. During the entire study, participants will be monitored for potential side-effects.

    Also known as: Proposed pharmacotherapy

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment - Upper Extremity (FMA-UE)

    The FMA-UE is a widely used, standardized test that measures movement, coordination, and reflexes of the arm, wrist, and hand after a stroke. Scores reflect the degree of motor impairment, with higher scores indicating better motor function (range 0-66).

    Time frame: Will be assessed at baseline, at 8 weeks, and at the end of the 12-week study

Secondary outcomes

  1. Action Research Arm Test (ARAT)

    The ARAT is a standardized test of upper limb function after stroke. It assesses the ability to grasp, grip, pinch, and move objects, with higher scores indicating better arm and hand function (range 0 to 57).

    Time frame: Will be assessed at baseline, at 8 weeks, and at the end of the 12-week study.

  2. Stroke Impact Scale (SIS)

    The SIS is a self-reported questionnaire that measures how stroke has affected daily activities, mobility, communication, emotion, memory, and quality of life. Higher scores reflect better function and well-being (range 0 to 100)

    Time frame: Will be completed at baseline, at 8 weeks, and at the end of the 12-week study.

  3. Mini Mental State Exam (MMSE scale)

    An 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language (range 0 to 30).

    Time frame: Will be completed at baseline, at 8 weeks, and at the end of the 12-week study.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels. 2011 Sep;26(5):502-10. doi: 10.1007/s00380-010-0093-1. Epub 2010 Dec 9. PubMed 21153029 ↗
  • Akhtar N, Singh R, Kamran S, Babu B, Sivasankaran S, Joseph S, Morgan D, Shuaib A. Diabetes: Chronic Metformin Treatment and Outcome Following Acute Stroke. Front Neurol. 2022 Apr 26;13:849607. doi: 10.3389/fneur.2022.849607. eCollection 2022. PubMed 35557626 ↗
  • Arbelaez-Quintero I, Palacios M. To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents. Stroke Res Treat. 2017;2017:9756429. doi: 10.1155/2017/9756429. Epub 2017 May 28. PubMed 28634570 ↗
  • Bourget C, Adams KV, Morshead CM. Reduced microglia activation following metformin administration or microglia ablation is sufficient to prevent functional deficits in a mouse model of neonatal stroke. J Neuroinflammation. 2022 Jun 15;19(1):146. doi: 10.1186/s12974-022-02487-x. PubMed 35705953 ↗
  • Brown T, Forster RB, Cleanthis M, Mikhailidis DP, Stansby G, Stewart M. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2021 Jun 30;6(6):CD003748. doi: 10.1002/14651858.CD003748.pub5. PubMed 34192807 ↗
  • Choi BR, Kim DH, Back DB, Kang CH, Moon WJ, Han JS, Choi DH, Kwon KJ, Shin CY, Kim BR, Lee J, Han SH, Kim HY. Characterization of White Matter Injury in a Rat Model of Chronic Cerebral Hypoperfusion. Stroke. 2016 Feb;47(2):542-7. doi: 10.1161/STROKEAHA.115.011679. Epub 2015 Dec 15. PubMed 26670084 ↗
  • Deguchi I, Furuya D, Fukuoka T, Tanahashi N. Effects of telmisartan on the cerebral circulation of hypertensive patients with chronic-stage stroke. Hypertens Res. 2012 Dec;35(12):1171-5. doi: 10.1038/hr.2012.105. Epub 2012 Jul 5. PubMed 22763480 ↗
  • Dobkin BH. Clinical practice. Rehabilitation after stroke. N Engl J Med. 2005 Apr 21;352(16):1677-84. doi: 10.1056/NEJMcp043511. PubMed 15843670 ↗
  • Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997 Dec;103(6):491-7. doi: 10.1016/s0002-9343(97)00254-4. PubMed 9428832 ↗
  • Grissi M, Boudot C, Assem M, Candellier A, Lando M, Poirot-Leclercq S, Boullier A, Bennis Y, Lenglet G, Avondo C, Lalau JD, Choukroun G, Massy ZA, Kamel S, Chillon JM, Henaut L. Metformin prevents stroke damage in non-diabetic female mice with chronic kidney disease. Sci Rep. 2021 Apr 2;11(1):7464. doi: 10.1038/s41598-021-86905-9. PubMed 33811249 ↗
  • Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. J Hypertens. 2010 Aug;28(8):1730-7. doi: 10.1097/HJH.0b013e32833a551a. PubMed 20498620 ↗
  • Jin Q, Cheng J, Liu Y, Wu J, Wang X, Wei S, Zhou X, Qin Z, Jia J, Zhen X. Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. Brain Behav Immun. 2014 Aug;40:131-42. doi: 10.1016/j.bbi.2014.03.003. Epub 2014 Mar 12. PubMed 24632338 ↗
  • Jung KH, Chu K, Lee ST, Kim SJ, Song EC, Kim EH, Park DK, Sinn DI, Kim JM, Kim M, Roh JK. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther. 2007 Sep;322(3):1051-8. doi: 10.1124/jpet.107.120097. Epub 2007 May 30. PubMed 17538008 ↗
  • Kim YR, Kim HN, Hong KW, Shin HK, Choi BT. Anti-depressant effects of phosphodiesterase 3 inhibitor cilostazol in chronic mild stress-treated mice after ischemic stroke. Psychopharmacology (Berl). 2016 Mar;233(6):1055-66. doi: 10.1007/s00213-015-4185-6. Epub 2015 Dec 21. PubMed 26686236 ↗
  • Kim YR, Kim HN, Hong KW, Shin HK, Choi BT. Antidepressant Effects of Aripiprazole Augmentation for Cilostazol-Treated Mice Exposed to Chronic Mild Stress after Ischemic Stroke. Int J Mol Sci. 2017 Feb 8;18(2):355. doi: 10.3390/ijms18020355. PubMed 28208711 ↗
  • Li T, Zhang Y, Zhu B, Wu C, Chen Y. Telmisartan regulates the development of cerebral ischemia by alleviating endoplasmic reticulum stress. Pharmazie. 2018 Oct 1;73(10):585-588. doi: 10.1691/ph.2018.8592. PubMed 30223922 ↗
  • Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol. 2000 Sep;16(9):1123-32. English, French. PubMed 11021956 ↗
  • Liu Y, Tang G, Li Y, Wang Y, Chen X, Gu X, Zhang Z, Wang Y, Yang GY. Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion. J Neuroinflammation. 2014 Oct 15;11:177. doi: 10.1186/s12974-014-0177-4. PubMed 25315906 ↗
  • Loan A, Syal C, Lui M, He L, Wang J. Promising use of metformin in treating neurological disorders: biomarker-guided therapies. Neural Regen Res. 2024 May;19(5):1045-1055. doi: 10.4103/1673-5374.385286. PubMed 37862207 ↗
  • Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Barone Gibbs B, Beaton AZ, Boehme AK, Commodore-Mensah Y, Currie ME, Elkind MSV, Evenson KR, Generoso G, Heard DG, Hiremath S, Johansen MC, Kalani R, Kazi DS, Ko D, Liu J, Magnani JW, Michos ED, Mussolino ME, Navaneethan SD, Parikh NI, Perman SM, Poudel R, Rezk-Hanna M, Roth GA, Shah NS, St-Onge MP, Thacker EL, Tsao CW, Urbut SM, Van Spall HGC, Voeks JH, Wang NY, Wong ND, Wong SS, Yaffe K, Palaniappan LP; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-e913. doi: 10.1161/CIR.0000000000001209. Epub 2024 Jan 24. PubMed 38264914 ↗
  • Matsumoto S, Ohama R, Hoei T, Tojo R, Nakamura T. Two Cases Showing That Cilostazol Administration Leads to an Increase in Cerebral Blood Flow and Has a Positive Effect on Rehabilitation. Cureus. 2024 Mar 18;16(3):e56376. doi: 10.7759/cureus.56376. eCollection 2024 Mar. PubMed 38633955 ↗
  • Mendonca IP, Paiva IHR, Duarte-Silva EP, Melo MG, Silva RSD, Oliveira WH, Costa BLDSAD, Peixoto CA. Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsons disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. Int Immunopharmacol. 2022 Jan;102:108415. doi: 10.1016/j.intimp.2021.108415. Epub 2021 Dec 8. PubMed 34890997 ↗
  • Munoz-Arenas G, Pulido G, Trevino S, Vazquez-Roque R, Flores G, Moran C, Handal-Silva A, Guevara J, Venegas B, Diaz A. Effects of metformin on recognition memory and hippocampal neuroplasticity in rats with metabolic syndrome. Synapse. 2020 Sep;74(9):e22153. doi: 10.1002/syn.22153. Epub 2020 Apr 6. PubMed 32190918 ↗
  • Park WS, Jung WK, Lee DY, Moon C, Yea SS, Park SG, Seo SK, Park C, Choi YH, Kim GY, Choi JS, Choi IW. Cilostazol protects mice against endotoxin shock and attenuates LPS-induced cytokine expression in RAW 264.7 macrophages via MAPK inhibition and NF-kappaB inactivation: not involved in cAMP mechanisms. Int Immunopharmacol. 2010 Sep;10(9):1077-85. doi: 10.1016/j.intimp.2010.06.008. Epub 2010 Jun 19. PubMed 20601185 ↗
  • Pekna M, Pekny M, Nilsson M. Modulation of neural plasticity as a basis for stroke rehabilitation. Stroke. 2012 Oct;43(10):2819-28. doi: 10.1161/STROKEAHA.112.654228. Epub 2012 Aug 23. No abstract available. PubMed 22923444 ↗
  • Potter WB, O'Riordan KJ, Barnett D, Osting SM, Wagoner M, Burger C, Roopra A. Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One. 2010 Feb 1;5(2):e8996. doi: 10.1371/journal.pone.0008996. PubMed 20126541 ↗
  • Rogalewski A, Schabitz WR. Stroke recovery enhancing therapies: lessons from recent clinical trials. Neural Regen Res. 2022 Apr;17(4):717-720. doi: 10.4103/1673-5374.314287. PubMed 34472456 ↗
  • Ruddy RM, Adams KV, Morshead CM. Age- and sex-dependent effects of metformin on neural precursor cells and cognitive recovery in a model of neonatal stroke. Sci Adv. 2019 Sep 11;5(9):eaax1912. doi: 10.1126/sciadv.aax1912. eCollection 2019 Sep. PubMed 31535024 ↗
  • Saisho Y. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205. doi: 10.2174/1871530315666150316124019. PubMed 25772174 ↗
  • Sakamoto T, Ohashi W, Tomita K, Hattori K, Matsuda N, Hattori Y. Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-kappaB from the Toll-like receptor signaling pathways. Int Immunopharmacol. 2018 Sep;62:120-131. doi: 10.1016/j.intimp.2018.06.021. Epub 2018 Jul 10. PubMed 30005227 ↗
  • Senda J, Ito K, Kotake T, Kanamori M, Kishimoto H, Kadono I, Nakagawa-Senda H, Wakai K, Katsuno M, Nishida Y, Ishiguro N, Sobue G. Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study. Nagoya J Med Sci. 2019 Aug;81(3):359-373. doi: 10.18999/nagjms.81.3.359. PubMed 31579328 ↗
  • Shin HK, Lee HR, Lee DH, Hong KW, Lee JH, Park SY, Lee SJ, Lee JS, Lee WS, Rhim BY, Kim CD. Cilostazol enhances neovascularization in the mouse hippocampus after transient forebrain ischemia. J Neurosci Res. 2010 Aug 1;88(10):2228-38. doi: 10.1002/jnr.22376. PubMed 20175201 ↗
  • Tanaka K, Matsumoto S, Yamada T, Yamasaki R, Suzuki M, Kido MA, Kira JI. Reduced Post-ischemic Brain Injury in Transient Receptor Potential Vanilloid 4 Knockout Mice. Front Neurosci. 2020 May 12;14:453. doi: 10.3389/fnins.2020.00453. eCollection 2020. PubMed 32477057 ↗
  • Thoene-Reineke C, Rumschussel K, Schmerbach K, Krikov M, Wengenmayer C, Godes M, Mueller S, Villringer A, Steckelings U, Namsolleck P, Unger T. Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models. PLoS One. 2011;6(8):e23646. doi: 10.1371/journal.pone.0023646. Epub 2011 Aug 25. PubMed 21901125 ↗
  • Veerbeek JM, Langbroek-Amersfoort AC, van Wegen EE, Meskers CG, Kwakkel G. Effects of Robot-Assisted Therapy for the Upper Limb After Stroke. Neurorehabil Neural Repair. 2017 Feb;31(2):107-121. doi: 10.1177/1545968316666957. Epub 2016 Sep 24. PubMed 27597165 ↗
  • Venna VR, Li J, Hammond MD, Mancini NS, McCullough LD. Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke. Eur J Neurosci. 2014 Jun;39(12):2129-38. doi: 10.1111/ejn.12556. Epub 2014 Mar 21. PubMed 24649970 ↗
  • Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, Keller GM, Frankland PW, Kaplan DR, Miller FD. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell. 2012 Jul 6;11(1):23-35. doi: 10.1016/j.stem.2012.03.016. PubMed 22770240 ↗
  • Watanabe T, Zhang N, Liu M, Tanaka R, Mizuno Y, Urabe T. Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion. Stroke. 2006 Jun;37(6):1539-45. doi: 10.1161/01.STR.0000221783.08037.a9. Epub 2006 Apr 27. PubMed 16645134 ↗
  • Westphal LP, Widmer R, Held U, Steigmiller K, Hametner C, Ringleb P, Curtze S, Martinez-Majander N, Tiainen M, Nolte CH, Scheitz JF, Erdur H, Polymeris AA, Traenka C, Eskandari A, Michel P, Heldner MR, Arnold M, Zini A, Vandelli L, Coutinho JM, Groot AE, Padjen V, Jovanovic DR, Bejot Y, Breniere C, Turc G, Seners P, Pezzini A, Magoni M, Leys D, Gilliot S, Scherrer MJ, Kagi G, Luft AR, Gensicke H, Nederkoorn P, Tatlisumak T, Engelter ST, Wegener S; Thrombolysis in Ischemic Stroke Patients (TRISP) Study Group. Association of prestroke metformin use, stroke severity, and thrombolysis outcome. Neurology. 2020 Jul 28;95(4):e362-e373. doi: 10.1212/WNL.0000000000009951. Epub 2020 Jun 29. PubMed 32601121 ↗
  • Yang X, Shi X, Xue X, Deng Z. Efficacy of Robot-Assisted Training on Rehabilitation of Upper Limb Function in Patients With Stroke: A Systematic Review and Meta-analysis. Arch Phys Med Rehabil. 2023 Sep;104(9):1498-1513. doi: 10.1016/j.apmr.2023.02.004. Epub 2023 Mar 1. PubMed 36868494 ↗

Individual participant data

Plan to share: Yes — Primary and secondary outcome measures will be shared via publications (de-identified individual participant data will be included in the Supplementary Materials section of the manuscript).

Supporting information: Study protocol

Time frame: At the time of publication of the manuscript summarizing the results of the study. De-identified individual participant data will be included in the Supplementary Materials section of the manuscript

Access criteria: We plan to publish an open access manuscript summarizing the results of the study and providing (in the Supplementary Materials section of the manuscript) de-identified individual participant data. Hence, de-identified individual participant data will be accessible by the public at large.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2027, 19 months after the start.

Of 71 non-industry phase 1 interventional studies under Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 19 months is below that.

Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2026
First posted
May 15, 2026
StartActual
May 18, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07588932
Collaborators
Neuro-Innovators, Inc.
Responsible party
Qing Mei Wang, M.D. (Director of the Stroke Biological Recovery Laboratory, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
May 15, 2026
Start date
May 18, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 14, 2026

Study contacts

Madison Costa, OT
Contact
mcosta11@mgb.org
617-952-6388
Erin Foley, OT
Contact
efoley14@mgb.org
617-952-6388
Qing M Wang, MD, PhD
principal investigator · Spaulding Rehabilitation Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Metformin · Cilostazol

Start the discussion